Advanced Filters
noise

Nonalcoholic Steatohepatitis Clinical Trials

A listing of Nonalcoholic Steatohepatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 150 clinical trials
X Xiling Lin

The Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-Aged and Older Adults

Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a liver condition primarily driven by metabolic dysfunctions that may progress to hepatitis, cirrhosis, and hepatocellular carcinoma. It is also implicated in the development of other metabolic dysfunction-related diseases. MAFLD has emerged as a growing public health concern in China. Despite its …

40 - 75 years of age All Phase N/A
r ramy, draz

Pyramidal Versus Continuous Training Effects on Fatty Liver

exercise is very important maneuver in the control of elevated liver enzymes in complaint of fatty liver .. the exercise forma are many.. from these exercises, pyramidal training or continues aerobic one.

37 - 51 years of age Female Phase N/A
A Angie Figueroa

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.

16 - 20 years of age All Phase 2
A Alok Bapatla, MD

Milk Thistle Clinical Trial in Pediatric NAFLD

Pediatric Fatty Liver disease is a growing problem in the United States and is expected to be the leading cause of Liver Transplantation in Adults in 20 years. Following lifestyle changes such as diet restrictions and exercise may be difficult to consistently maintain. The purpose of this study is to …

9 - 22 years of age All Phase 2
J Julie Marois, MSc

Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD

This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content, cardiometabolic risk factors and gut microbiota among both men and women with MASLD.

18 - 75 years of age All Phase N/A

Reversal of Lipid-Induced Insulin Resistance

The purpose of this study is to examine whether weight reduction decreases intramyocellular (IMCL) and hepatic lipid content, and improves insulin sensitivity of muscle and fat tissue in people who are insulin resistant and have a family history of type 2 diabetes. Hepatic mitochondrial oxidation will be assesses using a …

18 - 90 years of age All Phase N/A
G Giovanni De Pergola, Professor

Evaluation of Gut Permeability in Patients Affected by Obesity and NAFLD: Influence of Ketogenic Diet.

This study is open label, with one arm only. In this study will be enrolled patients with obesity (BMI more than 30). Aim of the study is to determine the influence (if any) of a very low calorie ketogenic diet (VLCKD) on gut permeability and liver steatosis. The first objective …

18 - 65 years of age All Phase N/A
E Endrit Shahini, MD

Effects of Two Different Exercise Programs and Diet in Obese Subjects With NAFLD

The aim of the study is to estimate the effectiveness of two different exercise programs combined with the Mediterranean diet versus diet alone on inflammatory status in subjects aged 18-65 years with obesity (BMI>30) and Non-Alcoholic Fatty Liver Disease (NAFLD) (CAP >248 dB/m).

18 - 65 years of age All Phase N/A
P Parco M. Siu, PhD

Vigorous- Versus Moderate-intensity Exercise to Reduce Liver Fat in Adults With Obesity and NAFLD

Non-alcoholic fatty liver disease (NAFLD) arising from obesity has become a global health concern. Although exercise is a cornerstone approach for managing NAFLD, detailed exercise prescription guidelines are unavailable. According to World Health Organization (WHO) recommendations, 1 minute of vigorous-intensity physical activity can achieve equivalent health benefits to 2 minutes …

18 - 69 years of age All Phase N/A
A Angelos Daniilidis, MD, PhD

Effect of a GnRH Analog on Hepatic Steatosis

Menopause increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD), possibly owing to the abrupt lack of estrogen. Gonadotropin-releasing hormone (GnRH) treatment in endometriosis is regarded as a model of pharmaceutical menopause. Thus, the effect of goserelin acetate, a GnRH analog that results in transient menopause, on hepatic steatosis …

18 - 45 years of age Female Phase 4

Simplify language using AI